Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$103.22 USD

103.22
3,056,704

+0.26 (0.25%)

Updated Aug 8, 2025 03:51 PM ET

After-Market: $103.11 -0.11 (-0.11%) 4:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Alcon (ALC) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are bullish about Alcon (ALC) owing to solid demand, strong commercial execution and pricing improvements across the Surgical and Vision Care franchises.

Zacks Equity Research

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

Zacks Equity Research

Alcon (ALC) Surgical End Market Grows, Vision Care Sales Rise

by Zacks Equity Research

In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.

Zacks Equity Research

Here's Why Investors Should Hold Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology's (ALGN) Invisalign portfolio expansion and strategic alliances.

Zacks Equity Research

Why You Should Add Humana (HUM) Stock to Your Portfolio Now

by Zacks Equity Research

Humana's (HUM) strength in Individual Medicare Advantage business and state-based contract wins are likely to be major tailwinds.

Zacks Equity Research

Quest Diagnostics' (DGX) New Pact to Get Home Fertility Test

by Zacks Equity Research

The Proov Confirm home collection kit can be purchased now on Quest Diagnostics' questhealth.com for $29.

Zacks Equity Research

3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Zacks Equity Research

Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.

Zacks Equity Research

DexCom's (DXCM) G7 CGM System Gets Nod From Health Canada

by Zacks Equity Research

DexCom's (DXCM) G7 CGM System's latest approval by Health Canada is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

Zacks Equity Research

LabCorp (LH) Partners With Forge Biologics for Gene Therapies

by Zacks Equity Research

LabCorp's (LH) latest partnership will significantly assist patients gain access to cutting-edge, potentially life-saving medication.

Zacks Equity Research

3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

Zacks Equity Research

Here's Why You Should Buy Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard growth and raised guidance.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Zacks Equity Research

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.

Zacks Equity Research

Acadia Healthcare (ACHC) Inks JV to Better Serve New Hampshire

by Zacks Equity Research

Acadia Healthcare (ACHC) enters into a JV with New Hampshire-based SolutionHealth to build a behavioral health facility and address the dire need for advanced behavioral health services across the state.

Zacks Equity Research

Quest Diagnostics (DGX) Presents New Data on Disease Testing

by Zacks Equity Research

Quest Diagnostics (DGX) is dedicated to create cutting-edge laboratory tests to help assess patient risk for dementia and other degenerative diseases.

Zacks Equity Research

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are upbeat about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.

Zacks Equity Research

Baxter's (BAX) New Launch to Support Complex Critical Care Needs

by Zacks Equity Research

Baxter's (BAX) Progressa+ bed for the ICU is expected to enhance workflow and reduce strain on nursing resources.

Zacks Equity Research

Thermo Fisher's (TMO) New Launch to Advance Cancer Therapies

by Zacks Equity Research

Thermo Fisher's (TMO) Gibco OncoPro Tumoroid Culture Medium Kit is intended to increase researchers' access to sophisticated cancer models.

Zacks Equity Research

Walgreens (WBA) to Advance Diabetes Care at FFL Conference

by Zacks Equity Research

Walgreens (WBA) will sponsor Children with Diabetes' FFL event to make a difference in the lives of the 122 million individuals afflicted by diabetes and pre-diabetes.

Zacks Equity Research

Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Zacks Equity Research

Amedisys (AMED) to Advance Value-Based Care With Optum Merger

by Zacks Equity Research

Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) backed by the acquisition of Oak Street Health, which broadens its value-based primary care platform.

Zacks Equity Research

McKesson's (MCK) Latest Launch to Give Access to OTC Products

by Zacks Equity Research

McKesson's (MCK) latest launch is expected to meet the evolving needs and growing demand for quality OTC private-label health and wellness products.

Zacks Equity Research

Three Reasons to Add Masimo (MASI) Stock to Your Portfolio

by Zacks Equity Research

Masimo's (MASI) solid product suite raises optimism about the stock.